A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02115815 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: RSV sF 20 mcg
BIOLOGICAL: MEDI7510 (20 mcg RSV sF)
BIOLOGICAL: RSV sF 50 mcg
BIOLOGICAL: MEDI7510 (50 mcg RSV sF)
BIOLOGICAL: RSV sF 80 mcg
BIOLOGICAL: MEDI7510 (80 mcg RSV sF)

Sponsor

MedImmune LLC